Publication | Open Access

A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients

OncologyMedicineColorectal CancerMfolfox6 Versus BevacizumabCancer TreatmentPharmacologyRadiation OncologyPhase I/iiMolecular Oncology